![Aaron Goodman: For my fellow histiocytic malignancy enthusiasts!](https://oncodaily.com/pub/uploads/2023/07/Aaron-Goodman-e1723462958200-1280x1261.jpeg)
Photo from Aaron Goodman/X
Aug 22, 2023, 09:29
Aaron Goodman: For my fellow histiocytic malignancy enthusiasts!
Quoting Aaron Goodman on Twitter/X:
“For my fellow histiocytic malignancy enthusiasts!
Discontinuation of BRAF/MEK inhibitors in histiocytic malignancies.
Paper has limitations – majority will relapse off continuous therapy. That being said, many patients can be safely observed.”
For the article click here.
Source: Aaron Goodman/Twitter
Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2024, 18:11